 Skeletal muscle calcium phosphofructokinase chronic heart failure captopril double-blind placebo-controlled study effects angiotensin enzyme inhibitor captopril treatment weeks mg patients stable moderate heart failure patients placebo treatment groups comparable baseline Angiotensin II levels response therapy Skeletal muscle potassium magnesium chloride levels reference values Calcium subnormal reference range captopril treatment Phosphofructokinase rate-limiting glycolytic enzyme reference range response therapy conclusion stable moderate heart failure low levels skeletal muscle calcium phosphofructokinase activity metabolic changes normal levels captopril treatment